Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

F0175000

Flucytosin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

5-Fluorcytosin, 4-Amino-5-fluor-2-hydroxy-pyrimidin, Flucytosin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C4H4FN3O
CAS-Nummer:
2022-85-7
Molekulargewicht:
129.09
Beilstein:
127285
MDL-Nummer:
MFCD00006035
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329799634
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

flucytosine

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

298-300 °C (dec.) (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

NC1=NC(=O)NC=C1F

InChI

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

InChIKey

XRECTZIEBJDKEO-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Nukleosid-Analogon mit antimykotischen Aktivitäten. 5-FC wird durch Cytosindeaminase zu 5-Fluoruracil deaminiert, was zur RNA Fehlcodierung führt. 5-Fluorcytosin hemmt die DNA- und RNA-Synthese und stört die ribosomale Proteinsynthese.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Health hazard
GHS08

Signalwort

Warning

H-Sätze

H361

P-Sätze

P280

Gefahreneinstufungen

Repr. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

Micafungin sodium ≥97% (HPLC)

Sigma-Aldrich

SML2268

Micafungin sodium

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Amphotericin B Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1662

Amphotericin B

Fluconazol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1160

Fluconazol

Ketoconazol 99.0-101.0% (EP, titration)

Sigma-Aldrich

K1003

Ketoconazol

vibrant-m

Y0000005

Amphotericin B

Amphotericin B, gelöst powder, γ-irradiated, BioXtra, suitable for cell culture

Sigma-Aldrich

A9528

Amphotericin B, gelöst

[Flucytosine - a classical partner for combination therapy].
Annemarie Polak
Mycoses, 45 Suppl 3, 31-33 (2003-04-15)
W L Whelan
Critical reviews in microbiology, 15(1), 45-56 (1987-01-01)
In terms of genetically determined susceptibility to the clinical antifungal agent 5-fluorocytosine (5-FC), Candida albicans may be homozygous sensitive (FCY/FCY), homozygous resistant (fcy/fcy), or heterozygous (fcy/FCY). Although heterozygotes are only slightly resistant, they occur at significant frequency among clinical strains
Angela Loyse et al.
The Journal of antimicrobial chemotherapy, 68(11), 2435-2444 (2013-06-22)
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden
J E Bennet
Annals of internal medicine, 86(3), 319-321 (1977-03-01)
Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all three diseases has
A Vermes et al.
The Journal of antimicrobial chemotherapy, 46(2), 171-179 (2000-08-10)
Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. It has no intrinsic antifungal capacity, but after it has been taken up by susceptible fungal cells, it is converted into 5-fluorouracil (5-FU), which is further converted to metabolites
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.